Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDFR0209
- Development stage
- Phase 4
- Lead developer
- Ajou University School of Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**CDFR0209** is an investigational immediate-release oral fixed-dose combination of omeprazole 40 mg and sodium bicarbonate 1,100 mg developed by Ajou University School of Medicine for acid-related disorders, including gastroesophageal reflux disease and stomach ulcer. Omeprazole is a proton pump inhibitor that irreversibly inhibits the gastric hydrogen-potassium ATPase, suppressing gastric acid secretion; sodium bicarbonate rapidly neutralizes gastric acid and protects omeprazole from acid degradation to enable immediate release. In a randomized crossover pharmacodynamic study in healthy male volunteers, repeated CDFR0209 dosing produced steady-state reduction in integrated gastric acidity comparable with delayed-release omeprazole.
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on CDFR0209.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDFR0209.